Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China

OBJECTIVE: Limited economic evaluation data for rivaroxaban compared with standard of care (SoC) exists in China. The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban compared with current SoC (enoxaparin overlapped with warfarin) for the treatment of acute deep vein...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li, Wu, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394175/
https://www.ncbi.nlm.nih.gov/pubmed/32737096
http://dx.doi.org/10.1136/bmjopen-2020-038433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394175/
https://www.ncbi.nlm.nih.gov/pubmed/32737096
http://dx.doi.org/10.1136/bmjopen-2020-038433

Ejemplares similares